How life-science founders can detect a broken commercial thesis, protect runway, and rebuild investor confidence

Four questions investors should ask before treating life science IP as a defensible asset

Founders - stop expecting fundraising from VCs to be "fair". It just isn't. Talking pre-seed here. There are founders will real customers, product, and traction that will get lower valuation caps in...

Why your Go-To-Market plan must address “who fixes it, how fast, and what happens when it breaks”

CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug

How market structure determines whether strong execution can produce a venture-scale outcome.

Healthcare investment bankers advise on M&A, ECM, DCM, licensing deals, and strategic alternatives across pharma, biotech, medtech, and services.

Capital Strategy Beyond Equity for Life Science Companies

Telling Real Evidence from Mere Activity in Healthcare and Biotech Deals

5th Annual Competition for Healthcare Champions Rockefeller Center, New York Trials: June 12, September 18 Finals: October 16

You're not bad at AI. You were handed an ocean and told to swim. That's the whole problem. Not your brain. Not your age. Not some class you missed. AI got sold to you as one giant thing. So you fro...

A practical playbook for first-time therapeutics founders to link science, evidence, and market from Day 1

The 505(b)(2) pathway is the pharmaceutical industry’s most capital-efficient regulatory route, and it is widely misunderstood. Ask ten drug developers to explain it and you’ll get ten different…